In our meta-analysis, we identified six genes with high mutation prevalence in brain metastases, of particular interest for their potential role in brain metastatic process and resistance to first-line anti-cancer drugs: ESR1, ERBB2, EGFR, PTEN, BRCA2 and NOTCH1 (Figure 4). Here, PTEN is linked to cancer.